{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T11:28:43Z","timestamp":1770550123176,"version":"3.49.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zenoaq Inc."},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ama121008"],"award-info":[{"award-number":["JP24ama121008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>B-cell lymphoma in dogs is a common hematopoietic malignancy, often treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based chemotherapy, but long-term outcomes remain suboptimal. Although CD20 targeting has improved outcomes in humans with non-Hodgkin\u2019s lymphoma, it remains challenging in dogs because of the lack of effective anti-CD20 antibodies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>We aimed to assess the safety, efficacy, and B-cell depletion kinetics of a novel afucosylated chimeric anti-canine anti-CD20 antibody (4E1-7-B_f) combined with CHOP chemotherapy in dogs with untreated B-cell lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Thirteen client-owned dogs with high-grade B-cell lymphoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this open-label, single-arm, single-center clinical trial, dogs received 4E1-7-B_f with CHOP chemotherapy. Treatment response was assessed using the Veterinary Cooperative Oncology Group criteria, whereas progression-free survival (PFS), overall survival (OS), and adverse events (AEs), and peripheral B-cell kinetics were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All 13 dogs achieved complete response (CR), with a median time to CR of 3\u00a0weeks. The median PFS and OS were 340 (95% confidence interval [CI], 87-417) and 458 (95% CI, 196\u2013not estimable) days, respectively. The 1- and 2-year survival rates were 69.2% and 38.9%, respectively. Most AEs were mild to moderate. B-cell depletion lasted for &amp;gt;\u2009200\u00a0days in most dogs, with some remaining B-cells deficient for over 300\u00a0days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and clinical importance<\/jats:title>\n                    <jats:p>The combination of 4E1-7-B_f with CHOP chemotherapy showed promising efficacy and prolonged B-cell depletion. Although direct comparisons cannot be made because of the single-arm design, the results suggest a potential benefit over historical CHOP data. Additional randomized controlled trials are needed to confirm these findings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jvimsj\/aalaf039","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T09:02:39Z","timestamp":1768986159000},"source":"Crossref","is-referenced-by-count":0,"title":["Afucosylated anti-canine CD20 antibody combined with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in dogs with B-cell lymphoma"],"prefix":"10.1093","volume":"40","author":[{"given":"Takuya","family":"Mizuno","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University , Yamaguchi 753-8515 ,","place":["Japan"]},{"name":"Research Institute for Cell Design Medical Science, Yamaguchi University , Yamaguchi 753-8515 ,","place":["Japan"]},{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa , Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Harada","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa , Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanao","family":"Ichimata","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa , Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuzo","family":"Katayama","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa , Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Miyagi 980-8575,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinori","family":"Shiga","sequence":"additional","affiliation":[{"name":"Zenoaq Inc. , Fukushima 963-0102 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Tsukui","sequence":"additional","affiliation":[{"name":"Zenoaq Inc. , Fukushima 963-0102 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Toyoda","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa , Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Fukazawa","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa , Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukiko","family":"Matsuyama","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa , Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Igase","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University , Yamaguchi 753-8515 ,","place":["Japan"]},{"name":"Research Institute for Cell Design Medical Science, Yamaguchi University , Yamaguchi 753-8515 ,","place":["Japan"]},{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa , Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Japan Small Animal Cancer Center, Affiliated with the Japan Small Animal Medical Center Foundation, Tokorozawa , Saitama 359-0023 ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"2026020706124814400_ref1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.vetimm.2014.02.016","article-title":"Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications","volume":"159","author":"Ito","year":"2014","journal-title":"Vet Immunol Immunopathol"},{"key":"2026020706124814400_ref2","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1111\/jvim.17222","article-title":"Comparison of CHOP-19 and CHOP-25 for treatment of peripheral nodal B-cell lymphoma in dogs: a European multicenter retrospective cohort study","volume":"38","author":"Hawkes","year":"2024","journal-title":"J Vet Intern Med [Internet]"},{"key":"2026020706124814400_ref3","doi-asserted-by":"publisher","first-page":"E159","DOI":"10.1111\/vco.12364","article-title":"Retrospective analysis of factors affecting clinical outcome following CHOP-based chemotherapy in dogs with primary nodal diffuse large B-cell lymphoma","volume":"16","author":"Childress","year":"2017","journal-title":"Vet Comp Oncol"},{"key":"2026020706124814400_ref4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/01652176.2016.1152633","article-title":"Canine lymphoma: a review","volume":"36","author":"Zandvliet","year":"2016","journal-title":"Vet Q"},{"key":"2026020706124814400_ref5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/vco.12605","article-title":"Rabacfosadine for na\u00efve canine intermediate to large cell lymphoma: efficacy and adverse event profile across three prospective clinical trials","volume":"18","author":"Saba","year":"2020","journal-title":"Vet Comp Oncol"},{"key":"2026020706124814400_ref6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12917-018-1587-9","article-title":"Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma","volume":"14","author":"Sadowski","year":"2018","journal-title":"BMC Vet Res"},{"key":"2026020706124814400_ref7","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/vco.12847","article-title":"Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with high-grade B-cell lymphoma","volume":"20","author":"Gareau","year":"2022","journal-title":"Vet Comp Oncol"},{"key":"2026020706124814400_ref8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"2026020706124814400_ref9","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1056\/NEJMct1114348","article-title":"Anti-CD20 antibody therapy for B-cell lymphomas","volume":"366","author":"Maloney","year":"2012","journal-title":"N Engl J Med"},{"key":"2026020706124814400_ref10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020706124814400_ref11","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"2026020706124814400_ref12","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.tvjl.2005.03.005","article-title":"The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation","volume":"171","author":"Impellizeri","year":"2006","journal-title":"Vet J"},{"key":"2026020706124814400_ref13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3109\/10428194.2014.914193","article-title":"Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential","volume":"56","author":"Ito","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"2026020706124814400_ref14","doi-asserted-by":"publisher","first-page":"e0148366","DOI":"10.1371\/journal.pone.0148366","article-title":"The development of a recombinant scFv monoclonal antibody targeting canine CD20 for use in comparative medicine","volume":"11","author":"Jain","year":"2016","journal-title":"PloS One"},{"key":"2026020706124814400_ref15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.vetimm.2015.02.004","article-title":"Identification of a candidate therapeutic antibody for treatment of canine B-cell lymphoma","volume":"164","author":"Rue","year":"2015","journal-title":"Vet Immunol Immunopathol"},{"key":"2026020706124814400_ref16","doi-asserted-by":"publisher","DOI":"10.1111\/jvim.17080","article-title":"Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma","volume":"38","author":"McLinden","year":"2024","journal-title":"J Vet Intern Med."},{"key":"2026020706124814400_ref17","doi-asserted-by":"publisher","first-page":"11476","DOI":"10.1038\/s41598-020-68470-9","article-title":"Generation of a canine anti-canine CD20 antibody for canine lymphoma treatment","volume":"10","author":"Mizuno","year":"2020","journal-title":"Sci Rep"},{"key":"2026020706124814400_ref18","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1111\/jvim.12429","article-title":"Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma","volume":"28","author":"Morges","year":"2014","journal-title":"J Vet Intern Med"},{"key":"2026020706124814400_ref19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/vco.12677","article-title":"Veterinary cooperative oncology group-common terminology criteria for adverse events (VCOG-CTCAE v2) following investigational therapy in dogs and cats","volume":"19","author":"LeBlanc","year":"2021","journal-title":"Vet Comp Oncol"},{"key":"2026020706124814400_ref20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1476-5829.2009.00200.x","article-title":"Response evaluation criteria for peripheral nodal lymphoma in dogs (v1.0)\u2014a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"8","author":"Vail","year":"2010","journal-title":"Vet Comp Oncol"},{"key":"2026020706124814400_ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ani14202994","article-title":"Clinical outcome of multicentric lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) in small breed dogs","volume":"14","author":"Kim","year":"2024","journal-title":"Animals (Basel)."},{"key":"2026020706124814400_ref22","doi-asserted-by":"publisher","first-page":"e0325526","DOI":"10.1371\/journal.pone.0325526","article-title":"Characterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies","volume":"20","author":"Mizuno","year":"2025","journal-title":"PloS One"},{"key":"2026020706124814400_ref23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","article-title":"Infusion-related reactions to rituximab: frequency, mechanisms and predictors","volume":"15","author":"Paul","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"2026020706124814400_ref24","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","article-title":"Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia","volume":"63","author":"Plosker","year":"2003","journal-title":"Drugs."},{"key":"2026020706124814400_ref25","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1158\/1078-0432.CCR-08-1403","article-title":"Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin\u2019s lymphoma","volume":"15","author":"Terui","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026020706124814400_ref26","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.exphem.2009.12.007","article-title":"B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression","volume":"38","author":"Borgerding","year":"2010","journal-title":"Exp Hematol"},{"key":"2026020706124814400_ref27","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/1\/aalaf039\/66458979\/aalaf039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/40\/1\/aalaf039\/66458979\/aalaf039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:13:06Z","timestamp":1770462786000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/doi\/10.1093\/jvimsj\/aalaf039\/8429759"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,21]]}},"URL":"https:\/\/doi.org\/10.1093\/jvimsj\/aalaf039","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]},"article-number":"aalaf039"}}